Paolo Strati, MD
The University of Texas MD Anderson Cancer Center
Session Chair
Biography
Paolo Strati MD is currently an Associate Professor, with Term Tenure, Deputy Section Chief for Indolent B-cell Lymphomas, Fellowship Director and CARTOX Program Leader in the Department of Lymphoma and Myeloma with a joint appointment in the Department of Translational Molecular Pathology, at the University of Texas MD Anderson Cancer Center, in Houston, TX. He previously served as Assistant Professor at the Mayo Clinic, in Rochester (MN). Dr. Strati earned his medical degree cum laude from the San Raffaele University of Milan (Italy) in 2008, and completed an Internal Medicine Residency at the same institution and, subsequently, at the Mayo Clinic, in Rochester (MN). He also completed a Hematology-Oncology Fellowship at MD Anderson Cancer Center, a Leukemia and Lymphoma fellowship at the same institution, and a Malignant Hematology fellowship at the Barts Cancer Institute, in London (UK). Dr. Strati is a recognized expert in the field of immunotherapy and cellular therapy for the treatment of B-cell lymphoma, and he is the principal investigator of multiple clinical trials and translational projects related to this topic. He is author of several peer-reviewed manuscripts published on high impact journal, including Blood and Lancet Haematology, and he is regularly invited to present his work at international scientific meetings, including the American Society of Hematology and the American Society of Clinical Oncology conference. In light of his research accomplishments, he has received multiple grants and awards, including a NIH R21 grant, the Lymphoma Research Foundation Career Development Award and the Leukemia Lymphoma Society Career Development Award. Dr. Strati is committed to gain further insight into the biology of the lymphoma immune microenvironment, and to manipulate its components successfully, in order to develop novel effective therapies and to decrease the toxicity of treatment strategies already available for patients with B-cell lymphoma.
Financial Disclosure
Astrazeneca
Advisor
Ipsen
Advisor
Incyte
Advisor
Beigene
Advisor
ADC Therapeutics
Advisor
Kite-Gilead
Advisor
Roche Genentech
Consultant
Genmab Abbvie
Consultant
Lilly
Advisor
Novartis
Advisor
ALX Oncology
Researcher